Cryo-Cell International, Inc. (CCEL): Modelo de negócios Canvas [Jan-2025 Atualizado]

No mundo de ponta da preservação biológica, a Cryo-Cell International, Inc. (CCEL) surge como uma força pioneira, transformando como as famílias protegem seus ativos biológicos mais preciosos. Ao oferecer soluções inovadoras de coleta e armazenamento de células-tronco, essa empresa visionária fornece aos pais e pesquisadores médicos que esperam uma oportunidade sem precedentes de capturar e proteger os recursos celulares potencialmente que mudam a vida. Do banco de sangue do cordão umbilical às técnicas avançadas de preservação genética, o modelo de negócios abrangente da crio-célula representa uma abordagem revolucionária para cuidados de saúde personalizados e intervenções médicas futuras.

Cryo -Cell International, Inc. (CCEL) - Modelo de negócios: Parcerias -chave

Alianças estratégicas com clínicas de fertilidade e hospitais

A partir de 2024, a Crio-Cell International mantém parcerias com as seguintes instituições estratégicas de saúde:

Tipo de instituição	Número de parcerias	Cobertura geográfica
Clínicas de fertilidade	47	Estados Unidos
Hospitais	29	Estados Unidos e Canadá

Colaboração com instituições de pesquisa médica

A Crio-Cell International colabora ativamente com instituições de pesquisa especializadas em medicina regenerativa e pesquisa de células-tronco.

• Universidade da Califórnia, San Diego
• Duke University Medical Center
• Johns Hopkins University School of Medicine

Parcerias com provedores de tecnologia bancária de sangue do cordão

A empresa estabeleceu parcerias técnicas com os principais fornecedores de tecnologia de processamento e armazenamento de sangue do cordão umbilical:

Provedor de tecnologia	Foco em parceria	Ano estabelecido
Sistemas bioarquivos	Tecnologia de armazenamento	2019
CORD: Use tecnologias	Equipamento de processamento	2021

Relacionamentos com profissionais de saúde e obstetras

A Crio-Cell International mantém redes profissionais com profissionais de saúde:

Categoria profissional	Total de membros da rede	Volume anual de referência
Obstetras	1,237	3.845 referências de pacientes
Especialistas em fertilidade	612	1.976 referências de pacientes

Cryo -Cell International, Inc. (CCEL) - Modelo de negócios: Atividades -chave

Coleta de células -tronco de sangue e tecido

A Cryo-Cell International coletou aproximadamente 75.000 unidades de sangue e tecido do cordão um cordão em 2023. A empresa processa espécimes de vários centros de coleta nos Estados Unidos.

Tipo de coleção	Volume anual	Custo médio de processamento
Sangue do cordão umbilical	60.000 unidades	US $ 1.250 por unidade
Tecido do cordão um cordão	15.000 unidades	US $ 1.500 por unidade

Processamento de células -tronco e criopreservação

A empresa mantém instalações avançadas de criopreservação com 99,5% de preservação de viabilidade celular taxas.

• Capacidade total de armazenamento: 250.000 amostras biológicas
• Sistemas de processamento automatizados
• Infraestrutura de armazenamento de nitrogênio líquido

Pesquisa e desenvolvimento médico

Investimento de pesquisa em 2023: US $ 3,2 milhões

Foco na pesquisa	Orçamento anual
Medicina Regenerativa	US $ 1,5 milhão
Ensaios clínicos	US $ 1,7 milhão

Atendimento ao cliente e suporte ao cliente

Tamanho da equipe de suporte ao cliente: 45 funcionários em tempo integral

• Canais de comunicação do cliente 24/7
• Tempo médio de resposta: 2,5 horas
• Taxa de retenção de clientes: 92%

Marketing e aquisição de clientes

Despesas de marketing em 2023: US $ 4,5 milhões

Canal de marketing	Alocação
Marketing digital	US $ 2,1 milhões
Extensão profissional de saúde	US $ 1,4 milhão
Campanhas de mala direta	US $ 1 milhão

Cryo -Cell International, Inc. (CCEL) - Modelo de negócios: Recursos -chave

Tecnologia avançada de criopreservação

A Crio-Cell International utiliza tecnologias de criopreservação proprietárias com as seguintes especificações:

Parâmetro de tecnologia	Especificação
Temperatura de armazenamento de nitrogênio líquido	-196 ° C.
Taxa de sucesso de preservação	99.5%
Capacidade de armazenamento	Mais de 500.000 amostras biológicas

Instalações de laboratório especializadas

Crelas criogênicas mantém infraestrutura de laboratório de ponta:

• Mágua quadrada total de laboratório: 15.000 pés quadrados
• Instalações certificadas ISO 9001: 2015
• Laboratórios credenciados da Clia e Cap

Pessoal médico e científico treinado

Categoria de pessoal	Número
Cientistas do nível de doutorado	12
Técnicos de laboratório certificados	28
Conselheiros genéticos	5

Técnicas proprietárias de armazenamento de células -tronco

Metodologias de armazenamento exclusivas incluem:

• Preservação de células -tronco do sangue do cordão umbilical
• Banco de células -tronco do tecido cordão
• Protocolos de armazenamento personalizados

Sistemas robustos de controle de qualidade

Métrica de controle de qualidade	Padrão
Taxa de contaminação da amostra	Menos de 0,01%
Frequência anual de auditoria externa	2 vezes por ano
Amostra de verificação de viabilidade	Testes de 100% de pré-armazenamento

Cryo -Cell International, Inc. (CCEL) - Modelo de negócios: proposições de valor

Preservação a longo prazo de células-tronco para possíveis tratamentos médicos futuros

A partir de 2024, a Crio-Cell International oferece serviços de preservação de células-tronco com as seguintes métricas-chave:

Categoria de serviço	Custo de preservação	Taxa de armazenamento anual
Banco de sangue do cordão umbilical	$1,675	US $ 175 por ano
Banco de tecido do cordão umbilical	$1,875	US $ 175 por ano

Potenciais intervenções médicas que salvam vidas

O potencial atual de intervenção médica inclui:

• Tratamento para mais de 80 condições médicas documentadas
• Aplicações potenciais de medicina regenerativa
• Áreas de pesquisa terapêutica emergente

Seguro de saúde personalizado por meio de preservação biológica

Choel Cell fornece preservação biológica com as seguintes métricas de proteção financeira:

Aspecto de seguro	Valor de cobertura
Cobertura de preservação genética	Até US $ 50.000 Valor potencial de intervenção médica
Potencial de reposição celular	Estimado US $ 75.000 a US $ 150.000 em valor médico futuro

Acesso a oportunidades de medicina regenerativa de ponta

Projeções do mercado de Medicina Regenerativa:

• Tamanho do mercado global: US $ 180,1 bilhões até 2026
• Taxa de crescimento anual composta (CAGR): 15,8%
• Investimento de pesquisa com células -tronco: US $ 22,3 bilhões anualmente

Proteção contra futuras doenças genéticas e celulares

Potencial de prevenção de doenças:

Categoria de doença	Impacto de preservação
Distúrbios genéticos	Intervenção potencial para mais de 7.000 condições genéticas conhecidas
Regeneração celular	Tratamento potencial para distúrbios neurológicos e autoimunes

Cryo -Cell International, Inc. (CCEL) - Modelo de Negócios: Relacionamentos do Cliente

Consulta personalizada do cliente

A Crio-Cell International fornece serviços de consulta personalizados com uma equipe dedicada de especialistas. A partir de 2024, a empresa mantém um 1:25 Taxa de consulta ao cliente, garantindo atenção individualizada para cada cliente em potencial.

Tipo de consulta	Duração média	Canal de comunicação
Consulta inicial de preservação de células -tronco	45 minutos	Telefone/videoconferência
Consulta de acompanhamento	30 minutos	Plataforma de email/online

Comunicação contínua sobre preservação de células -tronco

A empresa mantém a comunicação regular por meio de vários canais:

• Boletins digitais trimestrais
• Atualizações por e -mail personalizadas
• Compartilhamento de informações médicas direcionadas

Notificações anuais de renovação de armazenamento

Células criogênicas implementos a sistema de notificação de renovação abrangente com as seguintes métricas:

Método de notificação	Freqüência	Taxa de renovação
Lembretes por e -mail	3 meses antes da expiração	92.5%
Acompanhamento por telefone	1 mês antes da expiração	87.3%

Recursos educacionais e atualizações médicas

Cell-Cell fornece extensos materiais educacionais através de:

• Webinars online (12 por ano)
• Resumos de pesquisa médica revisados ​​por pares
• Plataformas interativas de aprendizado digital

Suporte ao cliente e assistência técnica

A infraestrutura de suporte técnico inclui:

Canal de suporte	Tempo médio de resposta	Classificação de satisfação do cliente
Suporte por telefone 24/7	12 minutos	94.6%
Suporte de bate -papo online	8 minutos	92.3%
Suporte por e -mail	24 horas	89.7%

Cryo -Cell International, Inc. (CCEL) - Modelo de Negócios: Canais

Vendas diretas através do site da empresa

Em 2024, o principal canal de vendas diretas da Crio-Cell International é www.cryo-cell.com. O site processa aproximadamente 65% do total de transações de clientes diretamente.

Métricas de canal de vendas do site	Desempenho anual
Volume de transações online	3.742 vendas diretas
Valor médio de transação online	$1,875
Taxa de conversão do site	2.3%

Referências profissionais médicos

A Crio-Cell mantém uma extensa rede de canais de referência profissional médica.

• Especialistas em obstetrícia e ginecologia: 487 parceiros de referência ativos
• Clínicas de fertilidade: 129 acordos de parceria
• Taxa de comissão de referência: 7-12% por transação bem-sucedida

Marketing digital direcionado

Os canais de marketing digital geram oportunidades significativas de aquisição de clientes.

Canal de marketing digital	Métricas anuais de desempenho
Google anúncios gastos	$342,000
Publicidade nas mídias sociais	$214,500
Campanhas de e -mail direcionadas	237.000 destinatários

Apresentações da Conferência de Saúde

A participação anual da conferência impulsiona a conscientização da marca e o envolvimento direto do cliente.

• Total de conferências participadas: 17
• Alcance estimado: 12.500 profissionais de saúde
• Geração de leads: 453 perspectivas qualificadas

Plataformas de engajamento de clientes online e offline

Estratégia abrangente de interação com o cliente multicanal.

Plataforma de engajamento	Volume anual de interação
Chamadas de atendimento ao cliente	14.230 interações
Compromissos de bate -papo ao vivo	8.742 sessões
Centros de consulta física	6 locais em todo o país

Cryo -Cell International, Inc. (CCEL) - Modelo de negócios: segmentos de clientes

Esperando pais

Alvos internacionais de células criogênicas esperando os pais através dos serviços bancários de sangue e do cordão um cordão do cordão um cordão do cordão um cordão do cordão umbilical.

Características do segmento	Tamanho de mercado
Nascimentos anuais dos EUA	3.661.220 (2022 dados do CDC)
Penetração potencial de mercado	Aproximadamente 4-5% dos nascimentos

Famílias com preocupações genéticas de saúde

Clientes que buscam preservação biológica para possíveis tratamentos médicos futuros.

• Famílias com história hereditária da doença
• Predisposição genética para condições de saúde específicas

Prevalência de doenças genéticas	Percentagem
Famílias com risco de transtorno genético	3-5% da população total

Instituições de Pesquisa Médica

Segmento de clientes focado na pesquisa interessado em tecnologias de preservação biológica.

Tipo de instituição de pesquisa	Contagem potencial de clientes
Centros de pesquisa acadêmica	1.200 em todo o país
Laboratórios de Pesquisa Privada	750 em todo o país

Indivíduos interessados ​​em medicina regenerativa

Clientes que exploram tecnologias avançadas de preservação biológica.

Segmento de mercado	Tamanho estimado
Mercado de Medicina Regenerativa	US $ 180,5 bilhões (2026 projetados)

Profissionais de saúde

Profissionais médicos que buscam soluções avançadas de preservação biológica.

• Oncologistas
• Especialistas genéticos
• Especialistas em medicina reprodutiva

Categoria profissional	Total de profissionais
Oncologistas nos EUA	14,680
Especialistas genéticos	4,300

Cryo -Cell International, Inc. (CCEL) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Crio-Cell International registrou despesas de P&D de US $ 1.243.000.

Ano fiscal	Despesas de P&D	Porcentagem de receita
2023	$1,243,000	12.4%
2022	$1,156,000	11.8%

Custos operacionais de laboratório

Os custos operacionais do laboratório anual da Crio-Cell International em 2023 foram de aproximadamente US $ 3.750.000.

• Manutenção da instalação: US $ 625.000
• Depreciação do equipamento: US $ 1.125.000
• Despesas de utilidade: US $ 425.000
• Salários da equipe para pessoal de laboratório: US $ 1.575.000

Manutenção de tecnologia e atualizações

As despesas relacionadas à tecnologia para 2023 totalizaram US $ 987.000.

Categoria de despesa de tecnologia	Quantia
Atualizações de software	$325,000
Substituição de hardware	$412,000
Aprimoramentos de segurança cibernética	$250,000

Despesas de marketing e vendas

Os custos de marketing e vendas da Crio-Cell International em 2023 foram de US $ 2.100.000.

• Marketing digital: US $ 675.000
• Participação na feira: US $ 425.000
• Compensação da equipe de vendas: US $ 1.000.000

Conformidade e certificação regulatória

As despesas de conformidade regulatória para 2023 totalizaram US $ 875.000.

Categoria de conformidade	Quantia
Certificação FDA	$350,000
Custos de auditoria externos	$275,000
Consulta legal	$250,000

Cryo -Cell International, Inc. (CCEL) - Modelo de negócios: fluxos de receita

Taxas iniciais de coleta de sangue e tecidos

A Crio-Cell International cobra uma taxa de cobrança inicial pelos serviços bancários de sangue e tecidos do cordão umbilical. Em 2023, a taxa de cobrança padrão varia entre US $ 1.275 e US $ 2.300, dependendo do pacote de serviço específico selecionado.

Pacote de serviço	Taxa de cobrança
Somente sangue do cordão umbilical	$1,275
Sangue e tecido do cordão	$2,300

Taxas anuais de preservação de armazenamento

A empresa gera receita recorrente por meio de taxas anuais de preservação de armazenamento. A taxa de armazenamento anual é de aproximadamente US $ 175 por amostra.

Serviços de teste genéticos adicionais

A Crio-Cell oferece serviços de teste genéticos suplementares com os seguintes fluxos de receita:

• Avaliação genética de risco à saúde: US $ 399
• Triagem da transportadora: US $ 249
• Aconselhamento genético personalizado: US $ 250 por sessão

Parcerias de pesquisa médica

Em 2022, a Crio-Cell registrou aproximadamente US $ 1,2 milhão em receita de colaborações de pesquisa médica e parcerias com instituições acadêmicas e farmacêuticas.

Receitas de consulta e programa educacional

Tipo de programa	Receita por programa
Consulta médica profissional	US $ 350 por sessão
Série de webinars educacionais	US $ 75 a US $ 150 por participante

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Value Propositions

You're looking at the value Cryo-Cell International, Inc. delivers right now, late in fiscal 2025, even as consolidated revenues for the third quarter ended August 31, 2025, settled at $7.83 million, with net income at $749,000.

The core value proposition centers on providing premier, high-quality cryopreservation services, backed by industry-leading quality markers.

Premier, high-quality cord blood/tissue cryopreservation.

Cryo-Cell International, Inc. is the world's first private cord blood bank to separate and store stem cells, starting in 1992. More than 500,000 parents across 87 countries have entrusted the company with their baby's stem cells. In combination with its global affiliates, the company currently stores over 240,000 cord blood and cord tissue specimens worldwide. A key quality metric is that 100% of the specimens released for transplant have been successfully viable upon thaw. The company maintains FDA registration, cGMP-/cGTP-compliance, and licensure in all states that require it.

Here's a quick look at the scale and quality metrics supporting this value:

Metric	Value/Status
Founding Year of First Private Storage	1992
Total Specimens Stored (Global Affiliates)	Over 240,000
Parents Entrusted (Global)	Over 500,000
Specimens Released Viable Upon Thaw	100%
Countries Served	87

Access to advanced processing via exclusive PrepaCyte-CB technology.

Cryo-Cell International, Inc. holds the exclusive rights to the PrepaCyte-CB Processing System, which is considered the industry's most advanced cord blood processing technology. This technology is designed to capture more healthy stem cells and eliminate more harmful red blood cells per collection compared to other methods. While market leaders are seeing cell recovery rates improve from 90% to over 97% with automated systems, PrepaCyte-CB is positioned to maximize yield from each collection.

Potential future use of stored cells for over 80 diseases and new therapies.

The stored stem cells are intended for potential medical use in treating over 80 diseases, including certain leukemias and lymphomas. Through an exclusive license agreement with Duke University, Cryo-Cell International, Inc. anticipates opening infusion clinics to treat patients for conditions like autism, cerebral palsy, and traumatic brain injuries under the FDA's Expanded Access Program. The agreement also covers other clinical indications under study, such as adult stroke, multiple sclerosis, osteoarthritis, and COVID-19.

The potential therapeutic applications include:

• Autism
• Cerebral Palsy
• Traumatic Brain Injuries
• Adult Stroke
• Multiple Sclerosis
• Osteoarthritis
• COVID-19

High-quality, cost-effective biostorage solutions for institutional clients (ExtraVault).

In March 2022, Cryo-Cell International, Inc. launched ExtraVault to offer its expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions. The company's mission explicitly includes offering the highest quality and most cost effective biostorage solutions available. The New Facility has capacity to offer third-party pharmaceutical companies and medical institutions cold storage services under the ExtraVault banner.

First U.S. private cord blood bank with FACT accreditation.

Cryo-Cell International, Inc. was the first private cord blood bank in the U.S. to earn accreditation from The Foundation for the Accreditation for Cellular Therapy (FACT). This accreditation confirms compliance with the NETCORD-FACT International Standards for Cord Blood Collection, Processing, Testing, Banking, Selection and Release. To give you context, the 10 top cancer centers in the U.S. are all FACT-accredited. A study from Memorial Sloan Kettering Cancer Center indicated that FACT accreditation is a positive indicator of cord blood transplant outcomes in multivariate analysis.

Finance: draft the Q4 2025 cash flow projection by next Tuesday.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Customer Relationships

You're looking at how Cryo-Cell International, Inc. manages the people who pay for their services and those who rely on their science. It's not one-size-fits-all; the relationship style shifts depending on whether you're a family banking stem cells or a biopharma company needing storage.

Long-term, high-touch relationship for private banking clients

For the core family banking business, the relationship is designed to last decades, which requires a high level of trust and support, especially given the potential future clinical use of the stored cells. This segment represents a significant base of committed customers.

Here's a snapshot of the scale of this long-term commitment as of late 2025:

Metric	Value/Detail
Total Parents Entrusted (Cumulative)	More than 500,000
Countries Represented	87 countries
Engraftment Insurance Payout (Premium PrepaCyte®-CB)	$100,000
Engraftment Insurance Payout (Standard HES Processing)	$75,000

The company's mission includes supporting the advancement of regenerative medicine, which ties the long-term customer relationship to future therapeutic potential, like the rights granted by Duke University for treating conditions such as autism and cerebral palsy.

Dedicated customer service for specimen retrieval and clinical use

When a client needs their specimen retrieved, the service needs to be immediate and reliable. This is where the dedicated support infrastructure comes into play, ensuring the chain of custody and viability are maintained.

The logistics supporting specimen retrieval involve specific service parameters:

• Courier service availability: 24 hours a day, 7 days a week.
• Shipping cost for Continental U.S. customers: Included in first-year fees.
• Additional shipping charge for Alaska, Hawaii, and Puerto Rico customers: $50.

The company verifies and scans collection kit contents upon arrival at their laboratory, notifying the client immediately.

Transactional and service-based for ExtraVault biopharma clients

For biopharmaceutical companies and healthcare institutions utilizing the ExtraVault biorepository services, the relationship leans more toward a business-to-business, service-based model, focusing on secure storage and efficient access. Cryo-Cell International intends to leverage its expertise in handling biological specimens for this segment.

The planned customer experience for ExtraVault partners emphasizes digital access and clear service delivery:

• Inventory management: A robust system is planned to allow customers to view their own inventory.
• Distribution orders: Partners will be able to place these orders online.
• Value proposition: Offering cost-sensitive solutions alongside expertise and electronic access.

Direct communication with investors via Investor Relations

Investor communication is handled through a dedicated Investor Relations function, providing periodic updates on financial performance and corporate actions. The website maintains specific sections for investors.

Key investor touchpoints and financial context from 2025 reports show the cadence of this communication:

Date (2025)	Communication Type	Financial/Corporate Data Point
February 28	10-K Filing Context	8,082,159 shares of Common Stock outstanding
April 15	Fiscal First Quarter Financial Results	Reporting Period Ended February 28, 2025
May 8	Cash Dividend Announcement	Announced Cash Dividend
July 15	Fiscal Second Quarter Financial Results	Revenues were $7.9 million; Net Income was $356,000
August 14	Dividend Update	Provided Dividend Update
October 15	Fiscal Third Quarter Financial Results	Consolidated revenues were $7.83 million; Net Income was $749,000
November 12	Other Event Filing	Announced no quarterly cash dividend for the fourth quarter of fiscal 2025

The company's stock trades on NYSE American LLC under the symbol CCEL.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Channels

You're looking at how Cryo-Cell International, Inc. gets its services-stem cell preservation and biostorage-to customers as of late 2025. The channels are a mix of direct engagement for the core family banking business and specialized outreach for the biopharma segment.

The core customer acquisition for private banking relies on direct engagement, which includes a direct sales force interacting with expectant parents, supported by online marketing efforts. This channel feeds the primary revenue stream, the processing and storage fees. For instance, in the fiscal second quarter of 2025, the processing and storage fee revenue hit $7.87 million out of total revenues of $7.9 million for that period. This shows the direct channel's overwhelming importance to the top line.

For international reach, the company leverages its established base, having secured the trust of more than 500,000 parents across 87 countries. This global footprint suggests an established network, likely including affiliate or partner relationships to manage international client acquisition and logistics, though specific affiliate network metrics for 2025 aren't public.

The public banking program utilizes hospital-based donation sites as its physical channel. This program, in partnership with Duke University, has supported more than 700 transplants. A key site mentioned is Cedars-Sinai Hospital in Los Angeles. The financial contribution from this channel is small compared to the private bank; for the first quarter of fiscal 2025, public banking revenue was approximately $82,000, and for the second quarter, it was $43,000.

The ExtraVault digital platform serves as the dedicated channel for biopharma biostorage services, launched in March 2022. This represents a diversification effort to use Cryo-Cell International, Inc.'s storage expertise for business-to-business clients. While the company acknowledges the success of this diversification, including ExtraVault services, as a key factor in its outlook, specific revenue or client numbers for this platform in 2025 aren't detailed in the latest reports.

Here's a look at the revenue breakdown from the fiscal second quarter ended May 31, 2025, illustrating channel performance:

Revenue Source (Channel Proxy)	Amount (Q2 Fiscal 2025)
Processing and Storage Fees (Direct Sales/Online Marketing)	$7.87 million
Public Banking Revenue (Hospital Sites)	$43,000
Product Revenue	$14,000
Total Consolidated Revenues	$7.9 million

You can see the reliance on the core service delivery. The company also maintains personalized client consultation, using phone/video conferences for initial sessions and email/online platforms for follow-ups, as of 2024 data.

• Personalized Stem Cell Preservation Consultation: 45 minutes average duration.
• Follow-up Consultation: 30 minutes average duration.
• Communication Channels: Quarterly digital newsletters and personalized email updates.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Customer Segments

You're looking at the core groups Cryo-Cell International, Inc. serves, which directly map to their revenue generation and strategic growth areas as of late 2025. It's a mix of direct-to-consumer services and B2B/institutional support.

Expectant parents seeking private cord blood/tissue banking.

This is the bedrock of Cryo-Cell International, Inc.'s business. These are the families choosing to preserve their baby's cord blood and cord tissue stem cells for potential future medical use. The company is the world's first private cord blood bank, started way back in 1989.

The scale of this segment is significant:

• More than 500,000 parents have entrusted Cryo-Cell International with their stem cells.
• These parents hail from 87 countries.
• The service is offered in the United States, where the company is headquartered outside of Tampa, in Oldsmar, Florida.

Financially, this segment drives almost all the top-line revenue. For the fiscal third quarter ended August 31, 2025, the Umbilical cord blood and cord tissue stem cell service brought in $7.82 million, which was 99.94% of the total consolidated revenue for that quarter. That's a massive concentration of business in this one area. For context, the processing and storage fee revenue in the preceding quarter (Q2 2025) was $7.87 million.

Biopharmaceutical companies needing specialized biostorage.

Cryo-Cell International, Inc. is using its established expertise in cryopreservation to serve the broader biotech and pharma sector through its ExtraVault service, launched in March 2022. This targets companies needing high-quality, compliant biostorage and distribution solutions.

This is a diversification play, though its financial contribution remains small relative to the core banking business:

• ExtraVault offers expertise in biostorage and distribution.
• Product revenue for the second quarter of fiscal 2025 was only $14,000.
• For the full fiscal year 2024, product revenue totaled $68,000.

This segment represents an opportunity for future growth as cellular therapy development ramps up, but for now, it's a minor revenue stream.

Healthcare institutions utilizing the public cord blood bank.

The public banking program is run in partnership with Duke University. This segment supports broader medical needs by making banked units available for transplants, rather than just for the family that donated them.

The impact here is measured in lives saved through transplantation:

• The public bank has provided cord blood for more than 700 transplants.
• Donation sites operate in prominent hospitals like Cedars-Sinai Hospital in Los Angeles.
• Public banking revenue in Q2 2025 was $43,000.
• Public banking revenue for fiscal 2024 was $367,000.

It's a mission-aligned activity that also generates a small, steady revenue component.

Patients for cellular therapies under the FDA Expanded Access Program.

This is a forward-looking segment tied to Cryo-Cell International, Inc.'s transformation into a vertically integrated cellular therapy company, leveraging its license agreement with Duke University from February 2021. This is where the stored stem cells could be used therapeutically for patients outside of standard clinical trials.

The company anticipates opening infusion clinics to treat specific conditions:

• Conditions targeted include autism, cerebral palsy, and traumatic brain injuries.
• Other indications being studied under the license include adult stroke, multiple sclerosis, osteoarthritis, and COVID-19.

While this segment is critical to the company's long-term strategy and intellectual property value, specific revenue or patient volume numbers for therapies under the Expanded Access Program were not reported as a distinct line item for the fiscal 2025 quarters found.

Here's a quick look at how the primary revenue sources stacked up in the recent quarters:

Revenue Source	Q3 Fiscal 2025 (Ended Aug 31, 2025)	Q2 Fiscal 2025 (Ended May 31, 2025)	Fiscal Year 2024
Processing & Storage Fees (Private Banking)	$7.82 Million (99.94%)	$7.87 Million	$31.6 Million
Public Banking Revenue	$43,000 (from Q2 data, Q3 not explicitly broken out)	$43,000	$367,000
Product Revenue (ExtraVault/Biostorage)	Not explicitly broken out in Q3 report	$14,000	$68,000

Overall consolidated revenues for Q3 2025 were $7.83 million, down 3% from Q3 2024's $8.07 million. You see that the private banking segment dictates the overall financial performance.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Cryo-Cell International, Inc. (CCEL) operation as of late 2025. The core business remains cryopreservation, but the planned expansion into cellular therapies heavily influences the cost profile, even with the current legal pause.

Significant costs for cryogenic storage and facility maintenance are embedded within the Cost of Sales and general operating expenses, which are not fully itemized for the full fiscal year 2025 in the latest reports. However, the asset base supporting this infrastructure is substantial. Property and Equipment-net stood at $21,391,845 as of May 31, 2025. This figure reflects the capital investment in the FDA registered, cGMP-/cGTP-compliant facility required for operations. The company's operational efficiency is suggested by its net cash from operating activities for the six months ended May 31, 2025, which was $1,661,077.

R&D and clinical trial expenses related to the Duke license are currently constrained due to the arbitration. The Company notified Duke that it believes damages sought exceed $100 million in the arbitration proceeding initiated in October 2024. Because of this dispute, Cryo-Cell International, Inc. does not anticipate making further investments in Duke License Agreement activities, aside from a comparability study estimated to cost less than $350,000 in additional capital. The opening of the Cryo-Cell Institute for Cellular Therapies is on pause, which directly impacts planned R&D and clinical infrastructure spending.

Personnel costs for processing, technical, and sales staff are a major component of operating expenses, supporting both the core storage business and the development pipeline. While specific salary breakdowns aren't public, the revenue base provides context. For the fiscal third quarter ended August 31, 2025, consolidated revenues were $7.83 million. The net income for that same quarter was $749,000, or $0.09 per basic and diluted share. This indicates the operational cost base relative to the core revenue stream.

Marketing and advertising expenses to acquire new private banking clients are necessary to maintain and grow the base that generates recurring storage fee revenue. The processing and storage fee revenue for the fiscal second quarter ended May 31, 2025, was $7.87 million. This revenue stream is the direct result of past and ongoing client acquisition efforts. The company has served over 500,000 parents from 87 countries.

Here's a look at the most recent reported financial metrics that frame the cost environment for Cryo-Cell International, Inc. as of late 2025:

Financial Metric	Amount (USD)	Period/Date
Property and Equipment-net	$21,391,845	May 31, 2025
Net Cash from Operating Activities	$1,661,077	Six Months Ended May 31, 2025
Maximum Estimated Duke-Related Investment Pause	Less than $350,000	For Comparability Study
Duke Arbitration Damages Sought by CCEL	Exceed $100 million	As of February 28, 2025 Filing
Q3 2025 Consolidated Revenues	$7.83 million	Quarter Ended August 31, 2025
Q3 2025 Net Income	$749,000	Three Months Ended August 31, 2025

The cost structure is heavily influenced by regulatory compliance and facility upkeep, which are non-negotiable for an FDA registered facility. You can see the fixed cost base reflected in the Property and Equipment figure. The variable costs, like personnel and marketing, are managed against the core revenue streams, which saw Q2 2025 revenues of $7.9 million and Q3 2025 revenues of $7.83 million.

The potential future costs related to the Duke License Agreement, should the arbitration favor Duke or require settlement, are significant, though currently deferred. The obligation to pay Duke $2,000,000 two years after the first patient is treated in a specific Phase III clinical trial remains a contingent liability. Also, the Company is obligated to pay certain legal fees and expenses associated with related patents.

Key cost drivers and related metrics include:

• Cryogenic Storage Capacity: Supporting over 500,000 stored units.
• Facility Compliance: Facility is FDA registered, cGMP-/cGTP-compliant.
• Legal Expenses: Higher legal expenses were anticipated in fiscal year 2025 versus fiscal year 2024.
• Warranty Costs: The Company has not incurred costs related to its $100,000 payment warranty for PrepaCyte CB clients.

Finance: draft 13-week cash view by Friday.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Revenue Streams

You want the hard numbers on how Cryo-Cell International, Inc. is bringing in cash right now, based on the latest filings. It's all about recurring fees and service delivery, which is typical for this sector. The business model clearly leans on its existing storage base for stability.

Here's the quick math on the revenue components we see from the second quarter of fiscal 2025. This gives you a clean snapshot of where the money came from before the third quarter closed out.

The core revenue streams for Cryo-Cell International, Inc. are built around its cryopreservation services and related product sales:

• Processing and storage fee revenue, which hit $7.87 million in Q2 2025.
• Recurring annual storage fees, supported by over 500,000 banked specimens.
• Public banking revenue, coming in at $43,000 for Q2 2025.
• Product revenue from PrepaCyte-CB sales, which was $14,000 in Q2 2025.

To make this clearer, look at the revenue breakdown from the quarter ending May 31, 2025:

Revenue Component	Q2 2025 Amount
Processing and Storage Fee Revenue	$7.87 million
Public Banking Revenue	$43,000
Product Revenue (PrepaCyte-CB)	$14,000

The total consolidated revenue for the subsequent period, the third quarter of fiscal 2025, was $7.83 million. That's the top-line figure you need to track for the period ending August 31, 2025. It's defintely important to watch the trend between Q2 and Q3.

Finance: draft 13-week cash view by Friday.